Sana Biotechnology (SANA) Expected to Announce Earnings on Wednesday

Sana Biotechnology (NASDAQ:SANA - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Wednesday, May 14th. Analysts expect Sana Biotechnology to post earnings of ($0.22) per share for the quarter.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last released its quarterly earnings results on Monday, March 17th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.02. On average, analysts expect Sana Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sana Biotechnology Stock Down 8.6 %

SANA stock opened at $1.71 on Wednesday. The firm has a market cap of $385.57 million, a P/E ratio of -1.22 and a beta of 1.75. Sana Biotechnology has a 52-week low of $1.26 and a 52-week high of $10.23. The company's 50-day simple moving average is $1.98 and its 200-day simple moving average is $2.52.

Analysts Set New Price Targets

A number of research firms have recently commented on SANA. TD Cowen upgraded shares of Sana Biotechnology from a "hold" rating to a "buy" rating in a research report on Wednesday, January 8th. Jefferies Financial Group began coverage on Sana Biotechnology in a research note on Friday, March 14th. They set a "buy" rating and a $7.00 price objective for the company. Citizens Jmp raised Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 price target on the stock in a research note on Tuesday, March 18th. Finally, HC Wainwright reiterated a "buy" rating and set a $11.00 price target on shares of Sana Biotechnology in a research report on Thursday, April 24th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $10.80.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.